Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Definitions

• the present disclosure is directed to, among other things, methods for the treatment of depression.
• Orexins are neuropeptides expressed by neurons in the perifornical area, the dorsomedial hypothalamus and the lateral hypothalamus (de Lecea et al, 1998; Proc. Natl. Acad. Sci. U.S.A. 95, 322-327; Sakaurai et al, 1998, Cell 92, 573- 585). Orexinergic neurons project to many areas of the brain including other hypothalamic nuclei, the midline paraventricular thalamus, brain stem nuclei, the ventral tegmental area and nucleus accumbens shell. (Peyron et al, 1998, J. Neurosci.
• Orexin neuropeptides classified as either orexin-A or orexin-B, bind to the seven transmembrane G- protein coupled receptors orexin- 1 (OX1 R) and orexin-2 (OX2R) (de Lecea et al., 1998; Proc. Natl. Acad. Sci. U.S.A. 95, 322-327; Sakaurai et al, 1998, Cell 92, 573-585). While orexin-A is non-selective for OX1R and OX2R, orexin-B shows higher affinity for OX2R (Sakaurai et al, 1998, Cell 92, 573-585). Orexin receptor antagonists are classified as single orexin receptor (SORAs) or dual receptor antagonists (DORAs).
• SORAs single orexin receptor
• DORAs dual receptor antagonists
• orexins are also hypothesized to play a role in excessive arousal (e.g. hypervigilance, anxiety, somatic tension, agitation and/or excessive rumination) which occurs in subsets of patients with mood disorders.
• excessive arousal e.g. hypervigilance, anxiety, somatic tension, agitation and/or excessive rumination
• MDD Major Depressive Disorder
• methods of treating a subject suffering from or diagnosed with depression comprise administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R x -R 4 are defined herein, and wherein the compound of formula (I) is administered prior to sleep.
• the subject treated according to the methods described herein is not suffering from or diagnosed with an insomnia disorder.
• the compound of formula (I) is administered at night according to the methods described herein.
• FIGs. 1-2 are the mean plasma concentration-time profiles for [5(4,6-dimethyl- pyrinddin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-2-[l,2,3]triazol-2-yl-phenyl)- methanone (Compound A) formulations.
• FIGs. 3-8 are the composite plasma concentration-time profiles for Compound A formulations.
• FIGs. 9-11 are the individual and mean plasma pharmacokinetic parameters versus treatment plots for Compound A formulations.
• FIG. 12 is a line graph of the time (min) from lights out to 10 minutes of sleep vs. the change from baseline at day 10/11.
• FIG. 13 is a line graph of the time (min) of total sleep vs. the change from baseline at day 10/11.
• FIG. 14 is a line graph of the latency to persistent sleep (LPS) change in Hamilton Depression Rating Scale (HAM-D 6 ) score from baseline at day 10/11 vs. the HAM-D 6 change from baseline at day 11.
• LPS Hamilton Depression Rating Scale
• FIG. 15 is a line graph of the total sleep time (TST) change in HAM-D 6 score from baseline at day 10/11 vs. the ⁇ -De score change from baseline at day 11.
• FIG. 16 is the process flow chart regarding the preparation of the tablets used herein.
• depression includes major depressive disorder, persistent depressive disorder, depression associated with bipolar disorder (aka bipolar depression), seasonal affective disorder, psychotic depression, postpartum depression, premenstrual dysphoric disorder, situational depression, anhedonia, melancholy, mid-life depression, late-life depression, depression due to identifiable stressors, treatment resistant depression, or combinations thereof.
• the depression is major depressive disorder.
• the major depressive disorder is with melancholic features or anxious distress.
• the methods described herein are useful in the treatment of the core (or psychic) symptoms of depression. These symptoms include depressed mood and loss of interest or pleasure in nearly all activities.
• Sleep onset refers to the transition from wakefulness into non-rapid eye movement (NREM) sleep; and “sleep” generally refers to non-rapid eye movement (NREM) or rapid eye movement (REM) sleep.
• awake describes a reasonably alert state of consciousness characterized by alpha and beta waves as detected by electroencephalogram, voluntary rapid eye movements and/or eye blinks.
• an awake state may be characterized as the absence of NREM or REM sleep.
• night includes the period of time from sunset to sunrise, occurring once each twenty -four hours. In some embodiments, night refers to a timeframe in a twenty-four period in a day that precedes sleep by a subject.
• An "insomnia disorder” refers to a diagnosis using criteria found in the American Psychiatric Association's fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) and the Third Edition of the World Health Organization's International Classification of Sleep Disorders (ICSD-3). In some embodiments, an "insomnia disorder” includes the difficulty initiating or maintaining sleep and waking too early and/or obtaining non- restorative sleep, where the sleep difficulty results in some form of daytime impairment.
• treating shall include the management and care of a subject or patient (preferably mammal, more preferably human) for the purpose of combating a disease, condition, or disorder and include the administration of a compound described herein to prevent the onset of the symptoms or complications, alleviate the symptoms or complications, or eliminate the disease, condition, or disorder.
• treatment is used to encompass (a) reduction in the frequency of one or more symptoms; (b) reduction in the severity of one or more symptoms; (c) the delay or avoidance of the development of additional symptoms; and/or (d) delay or avoidance of the development of the disorder or condition, or any combination thereof.
• the terms “subject” and “patient” may be used interchangeably and refer to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
• the subject or patient has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented.
• the methods of treatment are directed to subjects or patients in need of such treatment, prevention or dosing regimen, more particularly to subjects or patients diagnosed with or exhibiting at least one symptom of depression (preferably, meeting the criteria for major depressive disorder or episode) regardless of type or underlying cause.
• the subject is not suffering from or diagnosed with an insomnia disorder.
• a subject in need thereof shall include any subject who has experienced or exhibited at least one symptom of the disorder, disease or condition to be prevented.
• a subject in need thereof may additionally be a subject (preferably a mammal, more preferably a human) who has not exhibited any symptoms of the disorder, disease or condition to be prevented, but who has been deemed by a physician, clinician or other medical profession to be at risk of developing said disorder, disease or condition.
• the subject may be deemed at risk of having new episodes of depression (and therefore in need of secondary prevention or preventive treatment) as a consequence of the subject's medical history, including, but not limited to, family history, pre-disposition, co-existing (comorbid) disorders or conditions, genetic testing, and the like.
• the compounds described herein are orexin-2 antagonists and may be used in the treatment of depression.
• the compounds are administered such that they have a time to maximal plasma concentration of less than about 3 hours, less than about 2 hours, and preferably less than about 1 hour, i.e., less than about 45 minutes, less than about 30 minutes, less than about 15 minutes, among others.
• the compound has an elimination half-life of about 4 hours and typically less than about 4 hours.
• certain compounds of the present disclosure have a half-life of about 2 to about 3 hours, e.g., about 2 hours, about 2.1 hours, about 2.2 hours, about 2.3 hours, about 2.4 hours, about 2.5 hours, about 2.6 hours, about 2.7 hours, about 2.8 hours, or about 2.9 hours to about 3 hours.
• the amount of the compound remaining in the subject upon waking is typically below the threshold required for pharmacodynamic effect.
• the compounds of the present disclosure typically have a pharmacodynamic effect from a dose level greater than about 5 mg.
• the compound has the structure of formula (I):
• R 1 is Ci-4 alkyl. In some embodiments, R 1 is CH 3 .
• R 2 is Ci-4 alkyl. In some embodiments, R 2 is CH 3 .
• R 3 is H or halogen. In some embodiments, R 3 is halogen. In other embodiments, R 3 is fluorine. In further embodiments, R 3 is H.
• R 4 is H or Ci-4 alkoxy. In some embodiments, R 4 is H. In further embodiments, R 4 is Ci_ 4 alkoxy. In other embodiments, R 4 is methoxy.
• Alkyl refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain.
• alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
• cycloalkyl refers to a saturated or partially saturated, monocyclic, fused poly cyclic, or spiro poly cyclic carbocycle having from 5 to 7 ring atoms per carbocycle.
• cycloalkyl groups include the following entities, in the form of properly bonded moieties:
• a "heterocycloalkyl” refers to a monocyclic ring structure that is saturated or partially saturated and has from 4 to 7 ring atoms per ring structure selected from carbon atoms and up to two heteroatoms selected from nitrogen, oxygen, and sulfur.
• the ring structure may optionally contain up to two oxo groups on sulfur ring members.
• Illustrative entities, in the form of properly bonded moieties include:
• heteroaryl refers to a monocyclic, fused bicyclic, or fused poly cyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 12 ring atoms per heterocycle.
• heteroaryl groups include the following entities, in the form of properly bonded moieties:
• Alkoxy includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, and so on.
• Halogen represents chlorine, fluorine, bromine or iodine.
• C 1-3 refers independently to embodiments that have one carbon member (Ci), embodiments that have two carbon members (C 2 ), and embodiments that have three carbon members (C 3 ).
• C n-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n ⁇ N ⁇ m, with m > n.
• Any formula given herein is intended to represent a compound having a structure depicted by the structural formula as well as certain variations or forms.
• a compound of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula.
• any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
• certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers.
• the compounds may include those described in US Patent No. 8,653,263 and US Patent Publication No. 2014/0171430, both of which are incorporated herein by reference.
• the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol- 2-yl]-(2-fluoro-6-[l ,2,3]triazol-2-yl-phenyl)-methanone or a pharmaceutically acceptable salt thereof.
• the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro- pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[l ,2,3]triazol-2-yl-phenyl)-methanone.
• the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol- 2-yl]-(2-fluoro-6-[l,2,3]triazol-2-yl-phenyl)-methanone hydrochloride.
• the compound is (5-(4,6-dimethylpyrirnidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol- 2(lH)-yl)(4-methoxy-2-(2H-l,2,3-triazol-2-yl)phenyl)methanone or a pharmaceutically acceptable salt thereof.
• the compound is (5-(4,6- dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H-l ,2,3- triazol-2-yl)phenyl)methanone.
• the compound is (5-(4,6- dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H-l ,2,3- triazol-2-yl)phenyl)methanone hydrate.
• the compound is (5-(4,6- dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H-l ,2,3- triazol-2-yl)phenyl)methanone hydrochloride hydrate.
• the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H- l ,2,3-triazol-2-yl)phenyl)methanone hydrobromide hydrate.
• any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compound, and mixtures thereof, even if such forms are not listed explicitly.
• a compound of Formula (I) or pharmaceutically acceptable salts of a compound of Formula (I) may be obtained as solvates.
• Solvates include those formed from the interaction or complexation of a compound with one or more solvents, either in solution or as a solid or crystalline form. In some embodiments, the solvent is water and then the solvates are hydrates.
• crystalline forms of a compound of Formula (I) or pharmaceutically acceptable salts of a compound of Formula (I) may be obtained as co-crystals.
• a compound of Formula (I) is obtained in a crystalline form.
• a crystalline form of a compound of Formula (I) is cubic in nature.
• pharmaceutically acceptable salts of compounds of Formula (I) are obtained in a crystalline form.
• compounds of Formula (I) are obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form.
• a compound of Formula (I) converts in solution between one or more crystalline forms and/or polymorphic forms.
• any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
• Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
• isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H, H, n C, 1 C, 14 C, 15 N, 18 0, 17 0, 1 P, 2 P, 5 S, 18 F, 6C1, 125 I, respectively.
• Such isotopically labeled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
• PET positron emission tomography
• SPECT single-photon emission computed tomography
• an 18 F or n C labeled compound may be particularly preferred for PET or an I 123 for SPECT studies.
• substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
• Isotopically labeled compounds described herein and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent.
• a "pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of a compound represented by Formula (I) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, G.S. Paulekuhn, "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", J. Med. Chem, 2007, 50:6665-72, S.M. Berge, “Pharmaceutical Salts”, J Pharm Sci., 1977, 66: 1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley -VCH and VHCA, Zurich, 2002.
• Examples of pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
• Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates,
• metaphosphates pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-l,4-dioates, hexyne-1,6- dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, ⁇ -hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates,
• the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, gly colic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspart
• the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
• an inorganic or organic base such as an amine (primary, secondary, or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
• suitable salts include organic salts derived from amino acids, such as N-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
• amino acids such as N-methyl-D-glucamine, lysine, choline, glycine and arginine
• ammonia carbonates, bicarbonates, primary, secondary, and tertiary amines
• cyclic amines such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine
• inorganic salts derived
• prodrugs of a compound of Formula (I) and treatment methods employing such pharmaceutically acceptable prodrugs are also contemplated.
• the term "prodrug” means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I).
• a “pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H.
• Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three, or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I).
• amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
• Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) as amides or alkyl esters.
• amides include those derived from ammonia, primary Ci- 6 alkyl amines and secondary di(Ci- 6 alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties.
• amides include those that are derived from ammonia, primary amines, and di(Ci- 2 alkyl)amines.
• esters include Ci- 7 alkyl, Cs-ycycloalkyl, phenyl, and phenyl(Ci- 6 alkyl) esters.
• esters include methyl esters.
• Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Fleisher, Adv. Drug Delivery Rev. 1996, 19, 115-130. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs.
• acyloxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs.
• Prodrugs of this type may be prepared as described in Robinson, J. Med. Chem. 1996, 39(1), 10- 18. Free amines can also be derivatized as amides, sulfonamides, or phosphonamides. All of these prodrug moieties may incorporate groups including ether (-0-), amine (-N-), and carboxylic acid (COO-) functionalities.
• a pharmaceutical composition may comprise (a) an effective amount of at least one compound described herein and (b) a pharmaceutically acceptable excipient.
• a "pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
• excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
• Delivery forms of the pharmaceutical compositions containing one or more dosage units of the compounds described herein may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art.
• the compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, ocular routes, or by inhalation.
• the preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, or liquid preparations.
• the compositions are formulated for intravenous infusion, topical administration, or oral administration.
• the compositions are formulated for immediate release.
• the compounds can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. In certain embodiments, the compounds may be taken with food.
• Oral tablets may include a compound mixed with pharmaceutically acceptable excipients such as inert fillers, diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents, glidants and preservative agents.
• suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, lactose monohydrate, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, hypromellose, and the like.
• Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
• Binding agents may include hypromellose (hydroxypropyl methylcellulose or HPMC), starch and gelatin.
• the lubricating agent if present, may be magnesium stearate, stearic acid, or talc.
• the glidant if present, may be silica (S1O 2 ) such as colloidal silica.
• the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
• Capsules for oral administration include hard and soft gelatin capsules.
• the compound may be mixed with a solid, semi-solid, or liquid diluent.
• Soft gelatin capsules may be prepared by mixing the compound with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
• Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid compositions may optionally contain
• suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like
• non-aqueous vehicles e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water
• preservatives for example, methyl or propyl p-hydroxybenzoate or sorbic acid
• wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
• the compounds described herein may also be administered by non-oral routes.
• the compounds may be formulated for rectal administration.
• parenteral use including intravenous, intramuscular, or intraperitoneal routes, the compound may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
• Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
• Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
• Illustrative infusion doses may range from about 1 to 1000 ⁇ g/kg/minute of the compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
• the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1 % to about 10% of drug to vehicle.
• administering the compound may utilize a patch formulation to affect transdermal delivery.
• Compounds may alternatively be administered by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
• the inventors found a surprising, robust antidepressant effect when using the compounds described on subjects diagnosed with depression. Although not intending to be limited by theory, it is believed that because the activity of orexin containing neurons is negligible during sleep (typically at night), the antidepressant efficacy of the compounds discussed herein is surprising. As disclosed herein, administration prior to sleep (typically at night) of the compounds of the disclosure is associated with statistically significant
• methods of treating a subject suffering from or diagnosed with depression comprise administering to a subject in need of such treatment an effective amount of a compound described herein.
• the compound is of formula (I).
• the compound is preferably administered once daily and is administered to the subject prior to sleep.
• the compound is administered within about 2 hours of sleep, within about 1 hour, or within about 30 minutes before sleep.
• the compound is administered at least about 4 hours before the subject wakes or intends to wake from sleep, including about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, or about 12 hours before the subject wakes or intends to wake from sleep.
• the compound is administered at least 6 hours to about 12 hours before the subject wakes or intends to wake from sleep.
• preferred are examples of time before the subject wakes or intends to wake from sleep.
• the compound is administered at night.
• the compound undergoes at least one half-life before the subject wakes from sleep. In other embodiments, the compound undergoes at least two half-lives, and preferably at least three half-lives before the subject wakes from sleep.
• the compound is below the threshold required for pharmacodynamic effect after about 6 to about 8 hours after administration of the compound.
• This differs from antidepressants in the art which are designed to achieve a steady state concentration of the antidepressant in the patient.
• the methods described herein differ in that after one to eight hours of administration of the drug, the concentration of the drug will fall below pharmacodynamic levels and remain at those levels for the remainder of the 24-hour treatment period until the next dose of drug is administered.
• Therapeutically effective amounts for the compounds described herein include amounts that elicit the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
• Optimal dosages to be administered may be readily determined by those skilled in the art, and may vary with the mode of administration, the strength of the preparation and the advancement of the disease condition. Such factors including the particular patient being treated, including patient's sex, age, weight, diet, time of administration and concomitant diseases, among others.
• the effective amount of each dose of the compounds described herein is about 0.001 to about 200 mg of compound per kg of subject's body weight per day, about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (examples of such dosage units include 2.5 mg, 5 mg, 10 mg, and 20 mg tablets).
• an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
• the effective amount of the compound described herein may also be described without reference to the weight of the subj ect. Accordingly, the effective amount of the compound is about 10 to about 60 mg. In some embodiments, the effective amount of the compound is about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg, or within a range defined by any two of these values.
• the effective amount of the compound may be administered in a single daily dose.
• the compound is administered daily and one or more symptoms of the depression is reduced or ameliorated within about 11 days of a first administration, i.e., day 1.
• Frequency adjustment can be accomplished by a one-time switch in frequency or may be determined over two or more administrations. By doing so, the attending physician or the like may determine an optimal frequency for administration and thereby tailor the administration to the patient.
• rescue doses refers to one or more additional doses of a compound described herein in addition to the regularly prescribed dose.
• the amount of a compound described herein in the rescue dose may be determined by the prescribing physician or clinician and will depend on any of the factors discussed herein.
• the rescue dose of a compounds described herein is the same as the effective dose used during the normal administration schedule. In other embodiments, the rescue dose differs from the effective dose used during the normal administration schedule.
• the maintenance of the response in a patient may be determined by for example, a clinician, physician, psychiatrist, psychologist, or other suitable medical professional. Additionally, maintenance of the antidepressant response may be established by for example, an absence of relapse of the depression (or one or more symptoms of the depression), an absence of the need for additional or alternate treatment(s) for the depression, or an absence of the worsening of the depression.
• the physician or attending clinician may utilize any technique known in the art including, without limitation, general patient evaluation, diagnostic questionnaires, and evaluations such as the Clinical Global Impression - Severity (CGI-S) scale, EuroQol; 5 dimension; 5 level (EQ-5D-5L), Patient Health Questionnaire- 9 Item (PHQ-9), Sheehan Disability Scale (SDS), Inventory of Depressive Symptomatology-Clinician rated, 30-item scale (IDS-C30), Montgomery-Asberg Depression Rating Scale (MADRS) questionnaire, Hamilton rating scale for depression (HAM-D or HDRS) Beck Scale for Depression, or Quick Inventory of Depressive Symptomology (QIDS).
• CGI-S Clinical Global Impression - Severity
• the frequency may be evaluated and/or changed if the score from one or more of the above-noted scales or questionnaire changes.
• the compounds may be used in combination with additional active ingredients in the treatment of the above conditions.
• the additional active ingredients may be administered simultaneously, separately or sequentially.
• the additional active ingredients are effective in the treatment of conditions, disorders, or diseases mediated by orexin activity, such as another orexin modulator or a compound active against another target associated with the particular condition, disorder, or disease.
• the combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of a compound herein), decrease one or more side effects, or decrease the required dose of the compound described herein or additional active agent.
• the additional active ingredient is an antidepressant.
• the additional active ingredient is a monoaminergic antidepressant.
• the second antidepressant may be a conventional drug used to combat depression such as N-methyl-D-aspartate receptor antagonists, norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), corticotropin releasing factor (CRF) antagonists, alpha-adrenoreceptor antagonists and atypical antidepressants.
• SSRIs selective serotonin reuptake inhibitors
• MAOIs monoamine oxidase inhibitors
• RIMAs reversible inhibitors of monoamine oxidase
• SNRIs noradrenergic and specific
• the N-methyl-D-aspartate (NMD A) receptor antagonist is ketamine including its racemates esketamine, arketamine, or combinations thereof.
• the norepinephrine reuptake inhibitor includes amitriptyline, clomipramine, doxepin, imipramine, trimipramine, amoxapine, desipramine, maprotiline, nortriptyline, protriptyline, reboxetine, or pharmaceutically acceptable salts thereof.
• the selective serotonin reuptake inhibitor includes fluoxetine, fluvoxamine, paroxetine, sertraline, or pharmaceutically acceptable salts thereof.
• the monoamine oxidase inhibitor includes isocarboxazid, phenelzine, tranylcypromine, selegiline and pharmaceutically acceptable salts thereof.
• the reversible inhibitor of monoamine oxidase includes moclobemide or pharmaceutically acceptable salts thereof.
• the serotonin and noradrenaline reuptake inhibitor includes venlafaxine or pharmaceutically acceptable salts thereof.
• the atypical antidepressant includes bupropion, lithium, nefazodone, trazodone, viloxazine, sibutramine, or pharmaceutically acceptable salts thereof.
• the second antidepressant includes adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, apelinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine, bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoproti
• the compound of formula (I) is co-administered with esketamine.
• the compound of formula (I) is administered separately from esketamine such as, e.g., sequentially.
• the compound of formula (I) may be administered prior or subsequent to esketamine.
• kits for administering one or more compounds described herein to a patient for the treatment of depression include one or more dosage units comprising an effective amount of one or more compounds described herein for administration to a patient and at a given frequency.
• the dosage unit may be formulated for delivery by any means.
• the dosage unit may be formulated for delivery by any means.
• the dosage unit is formulated for oral, intravenous, intranasal, intramuscular, sublingual, transdermal, otic, or rectal delivery. In certain embodiments, the dosage unit is formulated for oral delivery.
• the dosage unit may be formulated to contain any amount of a compound described herein, depending on the route of administration. Accordingly, each dosage unit may comprise the required dosage for the patient or may comprise a portion of a compound described herein which is required for a single dosage.
• kits are also optionally included in the kits.
• the questionnaire may be for use by the patient alone or in combination with a physician.
• the questionnaire may be useful for determining the level of depression of the patient at any stage of compound administration.
• the questionnaire is one or more of the questionnaires noted herein.
• kits may be organized to indicate a single formulation containing a compound described herein or combination of formulations, each containing a compound described herein.
• the composition may be sub-divided to contain appropriate quantities of a compound described herein.
• the unit dosage can be packaged compositions such as packeted powders, vials, ampoules, prefilled syringes, tablets, caplets, capsules, or sachets containing liquids.
• the compound described herein may be a single dose or for continuous or periodic discontinuous administration.
• a kit may include a compound described herein in each dosage unit. When varying concentrations of a compound described herein, the components of the composition containing the compound described herein, or relative ratios of the compound described herein or other agents within a composition over time is desired, a kit may contain a sequence of dosage units.
• the kit may contain packaging or a container with a compound described herein formulated for the desired delivery route.
• the kit may also contain dosing instructions, an insert regarding the compound described herein, instructions for monitoring circulating levels of the compound, or combinations thereof.
• Materials for using the compound may further be included and include, without limitation, reagents, well plates, containers, markers, or labels, and the like.
• Such kits may be packaged in a manner suitable for treatment of a desired indication
• kits may include, or be packaged with, instruments for assisting with the injection/administration of the compound to the patient.
• instruments include, without limitation, an inhalant, syringe, pipette, forceps, measuring spoon, eye dropper, or any such medically approved delivery means.
• Other instrumentation may include a device that permits reading or monitoring reactions in vitro.
• the compound may be provided in dried, lyophilized, or liquid forms.
• reagents or components are provided as a dried form, reconstitution generally is by the addition of a solvent.
• the solvent may be provided in another packaging means and may be selected by one skilled in the art.
• the package is a labeled blister package, dial dispenser package, or bottle.
• Methods for optimizing a dosage of the compound for a patient having or being predisposed to depression also are provided. These methods can include (a) administering an effective amount of the compound to the patient, (b) analyzing the effects of the compound, and (c) administering an effective amount of the compound to the patient less frequently of a defined duration.
• the present disclosure comprises at least the following aspects.
• a method of treating a subject suffering from or diagnosed with depression comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I):
• R 1 is C 1-4 alkyl
• R 2 is C 1-4 alkyl
• R 3 is H or halogen
• R 4 is H or C 1-4 alkoxy; or a pharmaceutically acceptable salt or hydrate thereof, wherein the compound is administered prior to sleep.
• Aspect 2 The method of aspect 1 wherein the subject is not suffering from or diagnosed with an insomnia disorder.
• Aspect 3 The method of any one of the preceding aspects, wherein R is halogen.
• Aspect 4 The method of any one of the preceding aspects, wherein R 3 is fluorine.
• Aspect 5 The method of any one of the preceding aspects, wherein R 4 is H.
• Aspect 6 The method of aspect 1 or 2, wherein R 4 is Ci- 4 alkoxy.
• Aspect 7 The method of any one of aspects 1 , 2, or 6, wherein R 4 is methoxy.
• Aspect 8 The method of any one of aspects 1 , 2, 6, or 7, wherein R 3 is H.
• Aspect 9 The method of any one of the preceding aspects, wherein R 1 is CH 3 .
• Aspect 10 The method of any one of the preceding aspects, wherein R 2 is CH 3 .
• Aspect 1 1. The method of aspect 1 or 2, wherein the compound is 5-(4,6- dimethyl-pyrirnidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[l ,2,3]triazol-2-yl- phenyl)-methanone or a pharmaceutically acceptable salt thereof.
• Aspect 12 The method of aspect 1, 2, or 11 , wherein the compound is 5-(4,6- dimethyl-pyrirnidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[l ,2,3]triazol-2-yl- phenyl)-methanone.
• Aspect 13 The method of aspect 1, 2, or 11 , wherein the compound is 5-(4,6- dimethyl-pyrirnidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[l ,2,3]triazol-2-yl- phenyl)-methanone hydrochloride.
• Aspect 14 The method of aspect 1 or 2, wherein the compound is (5-(4,6- dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H-l ,2,3- triazol-2-yl)phenyl)methanone or a pharmaceutically acceptable salt thereof.
• Aspect 15 The method of any one of aspects 1 , 2, or 12, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4- methoxy-2-(2H- 1 ,2,3-triazol-2-yl)phenyl)methanone
• Aspect 16 The method of any one of aspects 1 to 3, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H- 1 ,2,3-triazol-2-yl)phenyl)methanone hydrate.
• Aspect 17 The method of any one of aspects 1 to 3, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H- l ,2,3-triazol-2-yl)phenyl)methanone hydrochloride hydrate.
• Aspect 18 The method of any one of aspects 1 to 3, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)(4-methoxy-2-(2H- l ,2,3-triazol-2-yl)phenyl)methanone hydrobromide hydrate.
• Aspect 19 The method of any one of the preceding aspects, wherein the compound is administered at night.
• Aspect 20 The method of any one of the preceding aspects, wherein the compound is administered such that it has a time to maximal plasma concentration of less than about 1 hour.
• Aspect 21 The method of any one of the preceding aspects, wherein the compound has an elimination half-life of about 2 to about 3 hours.
• Aspect 22 The method of any of the preceding aspects, wherein the compound is administered to the subject about at least 4 hours before the subject intends to wake from sleep.
• Aspect 23 The method of any one of the preceding aspects, wherein the compound is below the threshold required for pharmacodynamic effect after about 6 to about 8 hours after administration of the compound.
• Aspect 24 The method of any one of the preceding aspects, wherein the compound undergoes at least two half-lives before the subject wakes from sleep.
• Aspect 25 The method of any one of the preceding aspects, wherein steady state of the compound is not achieved.
• Aspect 26 The method of any one of the preceding aspects, wherein the compound is administered daily.
• Aspect 27 The method of any one of the preceding aspects, wherein the compound is administered orally.
• Aspect 28 The method of any one of the preceding aspects, wherein the effective amount is about 0.05 to about 100 mg/kg/day.
• Aspect 29 The method of any one of the preceding aspects, wherein the effective amount is about 10 to about 40 mg.
• Aspect 30 The method of any one of the preceding aspects, wherein the compound is administered daily and one or more symptoms of the depression is reduced or ameliorated within about 11 days of a first administration.
• Aspect 31 The method of any one of the preceding aspects, wherein the depression comprises major depressive disorder, persistent depressive disorder, depression associated with bipolar disease, seasonal affective disorder, psychotic depression, postpartum depression, premenstrual dysphoric disorder, situational depression, anhedonia, melancholy, mid-life depression, late-life depression, depression due to identifiable stressors, treatment resistant depression, or combinations thereof.
• Aspect 32 The method of aspect 31 , wherein the depression is major depressive disorder.
• Aspect 33 The method of aspect 32, wherein the major depressive disorder is with melancholic features or anxious distress.
• Aspect 34 The method of any one of the preceding aspects, further comprising administering a second antidepressant.
• Aspect 35 The method of aspect 34, wherein said second antidepressant is a norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, monoamine oxidase inhibitor, reversible inhibitor of monoamine oxidase, serotonin and noradrenaline reuptake inhibitor, noradrenergic and specific serotonergic antidepressant, corticotropin releasing factor antagonist, alpha-adrenoreceptor antagonists, atypical antidepressant, NMDA antagonist, or combinations thereof.
• said second antidepressant is a norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, monoamine oxidase inhibitor, reversible inhibitor of monoamine oxidase, serotonin and noradrenaline reuptake inhibitor, noradrenergic and specific serotonergic antidepressant, corticotropin releasing factor antagonist, alpha-adrenoreceptor antagonists, atypical anti
• Aspect 36 The method of aspect 35, wherein said NMDA antagonist is esketamine.
• step b was performed using isotope labeled Intermediate 92, i.e., 2-(4,6-dimethy].pyrimidin-2-yl)octahydropyrrolo[3,4-c]pyrrole, bis-HCl salt, which was prepared using isotope labelled 2-chloro-4,6-dimethyl pyrimidine of the following structure:
• t1 ⁇ 2 terminal half-life defined as 0.693/ ⁇ ⁇ .
• Vd/F apparent volume of distribution after extravascular administration uncorrected for absolute bioavailability.
• Compound A plasma levels were determined using LC-MS/MS using the equipment and parameters set forth in Tables 1 -4.
• Compound B Stock Solution this solution was prepared by dissolving Compound B (1.00 mg) in 10.0 mL of the Stock Dilution Solvent (2.00 mL).
• Compound B Working Solution 200 mg/mL: Compound B Stock Solution (200 ⁇ ) was combined with the Stock Dilution Solvent (100 mL).
• the suspension containing Compound A was prepared by reconstituting a powder (100 mg Compound A) with hypromellose (5 mg/mL) solution to provide an oral 5 mg/mL oral suspension of Compound A.
• the hypromellose used for reconstitution is a 0.5% hypromellose solution in sterile water for injection.
• the vial with spin bar was placed on a magnetic stir plate and the speed was adjusted to gently create a vortex in the liquid. Once a gentle vortex was achieved, the speed of the stir bar was increased for a rapid vortex at 2500 RPM (about 2400 to about 2600).
• composition was mixed for a minimum of about 24 to about 36 hours.
• Tablets containing Compound A contained the components set forth in Table 5. Table 5
• step 3 The mixture of step 3 was blended for 5 minutes at 20 rpm.
• This study consisted of 3 phases: an eligibility screening examination (between 21 days and 2 days prior to first dose administration), a 3-way crossover single dose open-label treatment phase which consisted of 3 treatment periods separated by a washout period of at least 6 days between dosing, and a follow-up visit (within 7 to 14 days after last dose administration).
• Treatment A 20 mg oral suspension formulation of Compound A (fasted state)
• Treatment B 20 mg solid formulation of Compound A (fasted state)
• Treatment C 20 mg solid formulation of Compound A (semi-fasted state)
• a mixed-effect model was applied to the natural log transformed C max and AUC.
• the model included sequence, period, treatment as fixed effects, and subject as a random effect. For each of the parameters, the comparisons included: • The solid dosage formulation (fasted) vs. the oral suspension formulation (fasted)
• This example was performed as a multi-center, double-blind, diphenhydramine and placebo-controlled study. Men and women with a diagnosis of MDD between the ages of 18 and 64, inclusive, were enrolled. At screening, the subjects had a total score of > 30 on the IDS-C30, corresponding to moderate to severe depression.
• Blood and saliva were collected for the assessment of biomarkers, among others.
• Venous blood samples (3 mL each) were collected in fasting condition between 8:00 and 10:00 am for the determination of [5(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2- yl]-(2-fluoro-2-[l,2,3]triazol-2-yl-phenyl)-methanone plasma concentrations and biomarkers related to immune system activity, Hypothalamus pituitary adrenal (HP A) axis activation, neurotropic factors and metabolic factors were measured.
• Pharmacokinetic (PK) blood samples also were collected. Plasma samples were analyzed to determine concentrations of Compound A using LC-MS/MS.
• Saliva was collected for the measurement of concentrations of Cortisol. Saliva concentrations of Cortisol were added as a biomarker.
• PSG polysomnography
• Compound A was found to be an orally active, selective antagonist of the orexin-2 receptor. After oral administration of 20 mg, Compound A had a short time to maximal plasma concentrations (Tmax ⁇ 1 hour) and was characterized by a short half-life (2 - 3 hours). Daytime administration of Compound A induced somnolence in healthy subjects while nighttime administration reduced the latency to persistent sleep (LPS) and prolongs the total sleep time (TST) in subjects with insomnia disorder (ID). The magnitude of the effect of Compound A on LPS and TST is directly related to level of insomnia at baseline. See, FIGs. 12-15.
• a HDRSn total score was calculated by summing the 17 item scores taken during the study.
• a HDRSn total score ranges from 0 to 52, with higher scores indicating greater severity of depression.
• sleep-related items were removed from the HDRSn to calculate a (sleep item)-adjusted HDRS.
• an adjusted HDRSn total score was calculated by summing the item scores excluding the 3 insomnia questions (4-Insomnia Early, 5-Insomnia Middle and 6-Insomnia Late).
• a HDRSn adjusted total score ranges from 0 to 46.
• a 6-item subscale from the HDRSn (HAM-D 6 ) was analyzed and provided information to core depressive symptoms and is sensitive to treatment response.
• the six items included depressed mood, guilt feelings, work and interests, psychomotor retardation, psychic anxiety, and general somatics (tiredness and pains).
• the HAM-D 6 score was calculated by summing the 6 items scores, and ranges from 0 to 22. Higher scores indicate greater severity of core symptoms.
• TST is defined as total minutes spent in rapid eye movement (REM) and non-REM sleep. Compared to placebo, both Compound A and diphenhydramine increased TST overnight on Day 1/2. Because of an increase in TST in placebo-treated subjects on Day 10/11, the relative effect of Compound A and diphenhydramine were less pronounced. See, Table 9. Although the overall study population did not meet criteria for insomnia disorder (TST ⁇ 360 minutes), individual subjects had baseline TST values as low as 263 minutes. Thus, the population was mixed with respect to the presence of insomnia disorder.
• LPS Latency to Persistent Sleep
• antidepressant effect of Compound A was larger and clinically relevant. Surprisingly, the effect of Compound A was largely related to an effect on the core symptoms of depression and overall unrelated to its effect on sleep related items. The antidepressant effect was sustained at least 14 days after treatment discontinuation. Of importance, improvements were already observed on Day 11 (first assessment) and were sustained upon treatment discontinuation.
• Compound A may be used in an adjunctive therapy. Specifically, Compound A was administered to subjects diagnosed with MDD (i) as a monotherapy and (ii) in combination with a known anti-depressant and the symptoms of depression of the subjects evaluated using the HDRS17 and HAM-D6 scale
• Group 1 thirty seven subjects were randomly assigned (in a 2: 1 : 1 ratio) to 20 mg of Compound A, 25 mg diphenhydramine or placebo q.d. in the evening over 10 days.
• Group 2 ten subjects were randomly assigned (in a 2: 1 : 1 ratio) to 20 mg of Compound A, 25 mg diphenhydramine or placebo q.d. in the evening over 10 days.
• Each subject in Group 2 also took an amount of antidepressant selected from duloxetine, citalopram, paroxetine, or sertraline and as prescribed by their attending physician.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Biophysics (AREA)
• Inorganic Chemistry (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (38)

Applications Claiming Priority (2)

Publications (1)

Family

ID=59776691

Family Applications (1)

Country Status (35)

Families Citing this family (16)

Citations (6)

Family Cites Families (144)

• 2017
  • 2017-03-09 BR BR112018067906A patent/BR112018067906A2/pt not_active Application Discontinuation
  • 2017-03-09 SM SM20220239T patent/SMT202200239T1/it unknown
  • 2017-03-09 EP EP17764092.7A patent/EP3426251B1/en active Active
  • 2017-03-09 WO PCT/US2017/021565 patent/WO2017156266A1/en not_active Ceased
  • 2017-03-09 JP JP2018547296A patent/JP7066622B2/ja active Active
  • 2017-03-09 CN CN201780016369.3A patent/CN108883110B/zh active Active
  • 2017-03-09 KR KR1020187026455A patent/KR102448342B1/ko active Active
  • 2017-03-09 KR KR1020237025023A patent/KR20230116948A/ko not_active Ceased
  • 2017-03-09 PT PT177640927T patent/PT3426251T/pt unknown
  • 2017-03-09 PH PH1/2018/501903A patent/PH12018501903B1/en unknown
  • 2017-03-09 KR KR1020227033141A patent/KR102559922B1/ko active Active
  • 2017-03-09 US US15/454,628 patent/US10828302B2/en active Active
  • 2017-03-09 CN CN202210483090.9A patent/CN115154470B/zh active Active
  • 2017-03-09 LT LTEPPCT/US2017/021565T patent/LT3426251T/lt unknown
  • 2017-03-09 AU AU2017231828A patent/AU2017231828B2/en active Active
  • 2017-03-09 HU HUE17764092A patent/HUE058759T2/hu unknown
  • 2017-03-09 CR CR20180433A patent/CR20180433A/es unknown
  • 2017-03-09 IL IL319248A patent/IL319248A/en unknown
  • 2017-03-09 MD MDE20190089T patent/MD3426251T2/ro unknown
  • 2017-03-09 IL IL288321A patent/IL288321B2/en unknown
  • 2017-03-09 UA UAA201810094A patent/UA125873C2/uk unknown
  • 2017-03-09 SG SG11201807597UA patent/SG11201807597UA/en unknown
  • 2017-03-09 MX MX2018010852A patent/MX2018010852A/es unknown
  • 2017-03-09 KR KR1020257016875A patent/KR20250083571A/ko active Pending
  • 2017-03-09 PL PL17764092.7T patent/PL3426251T3/pl unknown
  • 2017-03-09 RS RS20220487A patent/RS63296B1/sr unknown
  • 2017-03-09 MA MA43468A patent/MA43468B1/fr unknown
  • 2017-03-09 MA MA43817A patent/MA43817B1/fr unknown
  • 2017-03-09 MY MYPI2018703204A patent/MY197558A/en unknown
  • 2017-03-09 HR HRP20220642TT patent/HRP20220642T1/hr unknown
  • 2017-03-09 EA EA201891930A patent/EA201891930A1/ru unknown
  • 2017-03-09 ES ES17764092T patent/ES2913469T3/es active Active
  • 2017-03-09 DK DK17764092.7T patent/DK3426251T3/da active
  • 2017-03-09 EP EP22168101.8A patent/EP4091634A1/en active Pending
  • 2017-03-09 CA CA2960253A patent/CA2960253A1/en active Pending
  • 2017-03-09 CA CA3016706A patent/CA3016706A1/en active Pending
  • 2017-03-09 SI SI201731154T patent/SI3426251T1/sl unknown
• 2018
  • 2018-08-29 IL IL261461A patent/IL261461B/en unknown
  • 2018-09-05 CL CL2018002533A patent/CL2018002533A1/es unknown
  • 2018-09-06 NI NI201800086A patent/NI201800086A/es unknown
  • 2018-09-10 SV SV2018005740A patent/SV2018005740A/es unknown
  • 2018-09-12 CO CONC2018/0009561A patent/CO2018009561A2/es unknown
  • 2018-09-18 DO DO2018000196A patent/DOP2018000196A/es unknown
• 2020
  • 2020-11-09 US US17/092,725 patent/US11241432B2/en active Active
• 2021
  • 2021-08-10 JP JP2021130744A patent/JP2021181474A/ja not_active Withdrawn
  • 2021-12-15 US US17/551,955 patent/US12201634B2/en active Active
• 2022
  • 2022-06-15 CY CY20221100412T patent/CY1125247T1/el unknown
  • 2022-11-09 JP JP2022179528A patent/JP7534373B2/ja active Active
  • 2022-11-29 AU AU2022279416A patent/AU2022279416C1/en active Active
• 2024
  • 2024-02-13 JP JP2024019351A patent/JP2024056847A/ja active Pending
• 2025
  • 2025-01-10 US US19/016,620 patent/US20250221992A1/en active Pending
  • 2025-05-20 AU AU2025203695A patent/AU2025203695A1/en active Pending

Patent Citations (6)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events